Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org February 9, 2026 Philippe Henry preprint
A novel treatment approach for treatment-resistant depression and chronic anxiety combines the rapid neuroplastic effects of the psychedelic 5-MeO-DMT with the anxiolytic properties of the cannabinoid THCV, delivered via a precision vaporization device. The THCV acts as a 'cushion' to prevent the panic and acute activity increase often triggered by high-potency psychedelics, while allowing the tryptamine to promote synaptic growth and reset the Default Mode Network. This synergistic combination aims to provide more effective and tolerable relief than existing antidepressants, which require weeks to work and do not address synaptic atrophy.